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Abstract
Background: Critically ill patients lose up to 2% of muscle mass per day. We assessed the feasibility of
administering a leucine-enriched essential amino acid (L-EAA) supplement to mechanically ventilated trauma
patients with the aim of assessing the effect on skeletal muscle mass and function.
Methods: A randomised feasibility study was performed over six months in intensive care (ICU). Patients received 5 g
L-EAA five times per day in addition to standard feed (L-EAA group) or standard feed only (control group) for up to 14
days. C-reactive protein, albumin, IL-6, IL-10, urinary 3-MH, nitrogen balance, protein turnover ([1-13C] leucine infusion),
muscle depth change (ultrasound), functional change (Katz and Barthel indices) and muscle strength Medical Research
Council (MRC) sum score to assess ICU Acquired Weakness were measured sequentially.
Results: Eight patients (9.5% of screened patients) were recruited over six months. L-EAA doses were provided on 91/
124 (73%) occasions. Inflammatory and urinary marker data were collected; serial muscle depth measurements were
lacking due to short length of stay. Protein turnover studies were performed on five occasions. MRC sum score could
not be performed as patients were not able to respond to the screening questions. The Katz and Barthel indices did
not change. L-EAA delivery was achievable, but meaningful functional and muscle mass outcome measures require
careful consideration in the design of a future randomised controlled trial.
Conclusion: L-EAA was practical to provide, but we found significant barriers to recruitment and measurement of the
chosen outcomes which would need to be addressed in the design of a future, large randomised controlled trial.
Trial registration: ISRCTN Registry, ISRCTN79066838. Registered on 25 July 2012.
Keywords: Muscle wasting, Essential amino acids, Leucine, Muscle ultrasound, Critically ill, Nitrogen balance, Protein
turnover, Mechanical ventilation, Trauma
Background
Critically ill patients lose up to 2% of muscle volume per
day over the first 10 days [1, 2] and physical disability
has been identified up to five years after Intensive Care
Unit (ICU) admission in severe lung injury patients [3].
Minimising muscle wasting is crucial to optimise recov-
ery. In elderly institutionalised patients, leucine-enriched
essential amino acid (L-EAA) supplementation twice
daily improved nutritional status, muscle function and
physical performance [4]. Leucine supplementation in-
creased muscle protein synthesis in elderly individuals in
the short term [5, 6]. This type of supplement has not
yet been studied in the critically ill, yet a recent review
suggested it warranted further investigation [7].
The aims of this feasibility study were fourfold:
1. To determine the expected rate of recruitment for a
future randomised controlled trial (RCT).
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2. To establish whether a mechanically ventilated
trauma population would represent a feasible
patient population to study for this intervention.
3. To determine whether it was possible to routinely
deliver a L-EAA supplement in ICU patients.
4. To test the feasibility of measuring muscle mass,
protein turnover, strength and physical function
outcomes for a future RCT.
Methods
This prospective randomised feasibility study was con-
ducted at a large London teaching hospital in the adult
ICU from May 2012 to December 2012.
Inclusion criteria were: age > 18 years; admission for
trauma (head or multiple trauma); expected to be mech-
anically ventilated for > 48 h; within 72 h of ICU admis-
sion. Exclusion criteria were: non-trauma admissions;
pregnant or lactating; contraindication to enteral feeding
or a pre-existing condition where muscle wasting was
exhibited, i.e. patients with congestive cardiac failure,
neuromuscular disorders, end-stage renal failure, chronic
obstructive pulmonary disease and liver cirrhosis.
Trauma patients were selected as these patients are
generally younger, fitter and usually present with fewer
co-morbidities than other ICU cohorts, thereby repre-
senting a more homogenous cohort. The onset of injury
can also usually be identified enabling baseline represen-
tation of muscle mass and the anticipated length of stay
for head or multiple trauma is often significant.
An independent research nurse performed the ran-
domisation of patients via computer-generated schedule
to either standard care (control group) or the L-EAA
supplement. A branched-chain amino acid ratio for val-
ine : leucine : isoleucine of 1 : 5 : 1 was used based on a
previous study where additional leucine was shown to
promote muscle protein synthesis [8]. In addition to
standard enteral feeding, patients in the treatment group
received a 5-g L-EAA powder dissolved in 100 mL of
sterile water five times per day via the enteral feeding
tube. This was continued for up to 14 days. Control pa-
tients received standard enteral feeding via ICU protocol.
No placebo was used since at the time of study design
the manufacturer could not supply an appropriate prod-
uct. The study was not blinded as the researcher was
also measuring the outcome.
Study outcome measures
The following measures of feasibility were collected: the
number of patients recruited compared with those
screened; compliance with administration of the L-EAA
dose; and the number and reason for missed outcome
measures (inflammatory markers, cytokines, nitrogen
balance studies, muscle depth change, protein turnover
and functional outcome measures).
Candidate outcome measures to determine rates of
muscle wasting, protein turnover, strength and physical
function were explored to examine their feasibility in a
large RCT. These were muscle depth change on ultra-
sound, whole-body protein turnover using an intraven-
ous (i.v.) infusion of 1–13C leucine, Katz and Barthel
indices to assess functional change and the Medical Re-
search Council (MRC) sum score to assess ICU-acquired
weakness (ICU-AW).
C-reactive protein (CRP) (mg/L), albumin (g/L), inter-
leukin (IL)-6 (pg/mL) and IL-10 (pg/mL) levels were
measured serially on days 1, 3, 7 and 14 of the study.
Cytokines were measured from plasma samples and ana-
lysed via enzyme-linked immunosorbent assay (ELISA)
using ELISA grade streptavidin HRP and human IL-10
and IL-6 duosets obtained from R&D systems, Oxford,
UK.
Muscle depth change (cm) was measured on alternate
days throughout the ICU admission. The protocol has
been described by Reid et al. [2], but, in brief, includes
taking muscle measurements from the bicep, forearm
and thigh and adding the measurements together to
obtain a total muscle depth (cm). Ultrasound measure-
ments were undertaken using a Sonosite M Turbo™
ultrasound machine with a 5-MHz linear array trans-
ducer (Sonosite Ltd., Hitchin, Hertfordshire, UK).
Urinary urea (mmol/24 h) and urinary 3-methylhistidine
(μmol/24 h) samples were collected on study days 1, 3, 7
and 14. 3-Methylhistidine (3-MH) i was used as a surrogate
marker for skeletal muscle breakdown. An amino acid ana-
lyser with cation exchange chromatography (JEOL UK Ltd.,
Hertfordshire, UK) was used to analyse samples with nin-
hydrin detection and one inferred standard. Urine urea was
measured by a kinetic urease using an Abbott Architect
assay with Abbott reagents (Abbott, Maidenhead, UK).
Nitrogen balance (= nitrogen in – nitrogen out) (g/
day) was calculated using both the British Dietetic Asso-
ciation’s Parenteral and Enteral Nutrition Group (PENG)
recommended equation and the Deacon equation [9]
(see Additional file 1).
Katz and Barthel indices were used to assess activities
of daily living data. The MRC sum score was used upon
awakening and at discharge from ICU as a measure of
strength and to determine presence of ICU-AW as rec-
ommended by International Guidelines [10].
To measure protein turnover a primed intravenous
infusion of 1–13C Leucine 1 mg/kg; 1 mg/kg/h (Mas-
sTrace, Somerville, MA, US) was administered for 3 h as
previously described [11] on days 1, 3, 7 and 14. Regular
blood and breath samples were taken for the meas-
urement of the enrichment of alpha-ketoisocaproic
acid (α-KIC), the concentration of leucine and the en-
richment of expired CO2 at – 10 min, 0 min, 150 min
(steady state), 160 min, 170 min and 180 min. Blood
Wandrag et al. Trials          (2019) 20:561 Page 2 of 6
samples were taken from indwelling arterial catheters
and breath samples were collected from the expira-
tory port of the ventilator (Servo 300, Siemens, Berlin,
Germany or Servo I, Maquet, Sweden) via a Douglas
bag with flow meter attached. Enteral feed was
stopped 5 h before and during the 3 h of the protein
turnover study (see Additional file 1 for protocol and
laboratory analysis).
Continuous variables are shown as median (95% confi-
dence interval) due to small sample size; categorical vari-
ables are shown as frequencies (%). Descriptive statistics
were performed using SPSS V.20 (IBM Corp. 2011).
Results
From 1 May 2012 until 31 December 2012, 324 patients
were admitted to intensive care. Eighty-four patients
(25.9%) were major trauma admissions and 8 (9.5%) of
these patients were recruited to this feasibility study. Pa-
tient recruitment is illustrated in Fig. 1.
Demographic data are summarised in Table 1.
The feasibility of data collection is described in
Table 2. Muscle ultrasound and protein turnover
data collection were much lower than anticipated be-
cause patients were transferred back to referring
hospitals earlier than anticipated. The Katz and
Barthel indices remained at zero for all patients
throughout the study and are considered inappropri-
ate for future use in ICU populations. Manual
Fig. 1 Patient recruitment for the feasibility study. CCF: congestive cardiac failure; EN: enteral nutrition; ICU: intensive Care Unit; L-EAA leucine-
enriched essential amino acid, NGT nasogastric tube, NOK next-of-kin. No research staff --> no reserach staff for recruitment and enrolment;
recent ICU admission- other hospital; re-admission - same hospital ICU
Table 1 Demographic data of trauma ICU patient cohort
Demographic factors Control (n = 4) L-EAA (n = 4)
Age (years) 60 (28–99) 53 (19–58)
Sex, n (% men) 2 (50) 4 (100)
BMI (kg/m2) 23 (20–28) 25 (21–28)
APACHE II (0–71) a 14 (13–20) 15 (11–22)
Injury Severity Score (0–75) b 27 (13–34) 42 (20–50)
Diagnosis, n (%)
Multiple trauma (no TBI) 1 (12.5) 1 (12.5)
TBI only 1 (12.5) 1 (12.5)
Trauma including TBI 2 (25) 2 (25)
ICU LOS (days) 5 (2–6) 10 (8–14)
Hospital LOS (days) 15 (4–29) 14 (8–30)
L-EAA leucine-enriched essential amino acid, IQR interquartile range, BMI body
mass index, APACHE II Acute Physiology and Chronic Health Evaluation II, TBI
traumatic brain injury, ICU Intensive Care Unit, LOS length of stay
Continuous variables shown as median (95% confidence intervals); categorical
variables shown as frequencies (%)
aHigher APACHE I scores indicate greater disease severity and correspond with
risk of death
bInjury Severity Score > 15 is defined as major trauma
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strength testing could not be performed as patients
were not able to respond appropriately to the
screening questions.
Discussion
This study was designed to investigate the feasibility
of undertaking a RCT providing a L-EAA supplement
to critically ill trauma patients to determine the effect
on muscle wasting and protein turnover. We found
significant barriers to recruitment and to measure-
ment of the chosen outcomes which would need to
be addressed in the design of a future, large RCT. Re-
cruitment was dependent on one researcher without
24 h availability. We also found the measurement of
some outcomes and frequency thereof to be very in-
tensive for each patient.
Specific recommendations for a future study include
the following:
In terms of recruitment, a multicentre design should
be considered, potentially as part of a trial group that
enables enrolment in multiple sites nationally and/or
internationally. The design of a future protocol should
allow co-enrolment with other studies, where feasible.
We would advise having multiple trained members of
staff available to recruit over 24 h, for seven days per
week.
In terms of the population studied, the trauma
population had some theoretical advantages, fewer
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Protein turnover study > 80 31% studies
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Nitrogen balance (PENG, g/day) > 80 81% calculated CRRT affecting urine sampling, urinary urea − 10.6 to 7.4 − 7.95
to 11
Nitrogen balance (Deacon, g/day) > 80 81% calculated CRRT affecting urine sampling, urinary urea − 6.2 to 7.4 − 3.3
to 11.2
Katz and Barthel indices > 90 100% tested Poor tests in this setting with substantial floor effect 0 0
MRC sum score > 90 0% completed No patient passed initial MRC screening questions (8/10
presented with traumatic brain injury)
– –
CRP C-reactive protein, IL-6 interleukin 6, IL-10 interleukin 10, L-EAA leucine-enriched essential amino acid, GI gastrointestinal, CRRT chronic renal replacement
therapy, 3-MH 3-methylhistidine, LOS length of stay, MRC Medical Research Council, RFCSA rectus femoris cross-sectional area
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co-morbidities, potentially fewer confounders and
known onset of injury. However, the dynamic nature
of this cohort was underestimated; they had multiple
procedures, interventions, admissions to theatre and
unexpected repatriation. This made data collection
difficult for an intensive physiological study such as
this. We would recommend not restricting recruit-
ment to a specific type of ICU patient but including
those who are expected to be ventilated for > 48 h
and perhaps those patients with high nutritional risk.
Provision of a L-EAA supplement is possible in an
ICU setting; however, minimising the number of doses
from five times a day to twice daily may aid delivery
without reducing any potential beneficial effect. Type
and dose of amino acid supplement as well as the best
phase of critical illness (acute, chronic, recovery phase) in
which to provide this [12] still needs to be explored thor-
oughly in future studies. Protein supplementation in con-
junction with physical activity or exercise may have the
best synergistic effect [13]. The current NEXIS (Nutrition
and Exercise in Critical Illness) Trial, ClinicalTrials.gov
Identifier NCT03021902, in which intravenous amino
acids is given alongside in-bed cycle ergometry, will aid to
explore this synergistic effect.
In terms of outcome measures, we would suggest that
a larger research team is required for such complex
outcome measures as stable isotope measurement in
ventilated patients. However, the number of staff per-
forming muscle ultrasound measurements should be
minimised due to the challenges of achieving good inter-
rater reliability. Serial muscle ultrasound measurement
over fewer data collection points, i.e. days 1 and 7, may
be more sensible. A longer follow-up period would be
required in a future amino acid dosing study to assess
the post-ICU phase. Patients should be followed up into
the ward and after the hospital admission so that longer-
term functional outcome measures could be assessed. A
mixture of nutritional, physical and functional outcome
measures should be included in this type of study. In-
flammatory markers and cytokine data were feasible to
collect on most occasions. Urinary measurements were
only missed due to renal replacement therapy. Serial
muscle ultrasound measurement over fewer data collec-
tion points, i.e. days 1 and 7, may be more sensible.
The Katz and Barthel indices demonstrated substantial
floor effects and were thus poor informers of functional
change in critically ill patients. MRC sum score assess-
ment is not advised in a majority head-injured trauma
population. Functional assessment tools require piloting
in future studies.
To our knowledge, this was the first study to assess
the feasibility of using a L-EAA supplement in mech-
anically ventilated trauma patients. Outcome measures
to assess protein turnover, muscle depth change and
markers of protein breakdown in conjunction with
functional outcome measures are not usually embed-
ded into nutrition trials in the ICU. As such, this
study should assist future investigators in considering
which ICU patient population and outcome measures
to study.
Conclusion
Amino acid supplementation is feasible in ventilated
critically ill patients; however, this study had some
major design limitations. Researchers need to consider
the study population carefully, perhaps considering in-
dividual phenotypes and including patients with high
nutritional risk, as well as the detailed clinical path-
way. The intervention needs careful consideration for
type, dose and timing in terms of phase of illness.
Studying interventions both in the ICU and post-ICU
phase may be most informative, while coupling amino
acids with physical activity. Muscle mass, functional
and quality of life outcome measures should be in-
cluded in future studies.
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